Report Detail
Global (United States, European Union and China) Postmenopausal Vaginal Atrophy Drugs Market Research Report 2019-2025
- RnM3623045 |
- 29 July, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
In 2019, the market size of Postmenopausal Vaginal Atrophy Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Postmenopausal Vaginal Atrophy Drugs.
This report studies the global market size of Postmenopausal Vaginal Atrophy Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Postmenopausal Vaginal Atrophy Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.
Market Segment by Product Type
Premarin
Vagifem
Estrace
Estring
Femring
Market Segment by Application
Vaginal Gels
Creams
Tablets
Rings
Patches
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Postmenopausal Vaginal Atrophy Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Postmenopausal Vaginal Atrophy Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Postmenopausal Vaginal Atrophy Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Premarin
- 1.3.3 Vagifem
- 1.3.4 Estrace
- 1.3.5 Estring
- 1.3.6 Femring
- 1.4 Market Segment by Application
- 1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application (2019-2025)
- 1.4.2 Vaginal Gels
- 1.4.3 Creams
- 1.4.4 Tablets
- 1.4.5 Rings
- 1.4.6 Patches
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size
- 2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2014-2025
- 2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2014-2025
- 2.2 Postmenopausal Vaginal Atrophy Drugs Growth Rate by Regions
- 2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions 2014-2019
- 2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
- 3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
- 3.4 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
- 3.6 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Premarin Sales and Revenue (2014-2019)
- 4.1.2 Vagifem Sales and Revenue (2014-2019)
- 4.1.3 Estrace Sales and Revenue (2014-2019)
- 4.1.4 Estring Sales and Revenue (2014-2019)
- 4.1.5 Femring Sales and Revenue (2014-2019)
- 4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type
- 4.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type
- 4.4 Postmenopausal Vaginal Atrophy Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application
6 United States
- 6.1 United States Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
- 6.2 United States Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
- 6.3 United States Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
- 7.2 European Union Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
- 7.3 European Union Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application
8 China
- 8.1 China Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
- 8.2 China Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
- 8.3 China Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
- 9.2 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
- 9.3 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application
- 9.4 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Postmenopausal Vaginal Atrophy Drugs Sales by Countries
- 9.4.2 Rest of World Postmenopausal Vaginal Atrophy Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Actavis plc
- 10.1.1 Actavis plc Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.1.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.1.5 Actavis plc Recent Development
- 10.2 Bionovo, Inc.
- 10.2.1 Bionovo, Inc. Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.2.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.2.5 Bionovo, Inc. Recent Development
- 10.3 Endoceutics, Inc.
- 10.3.1 Endoceutics, Inc. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.3.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.3.5 Endoceutics, Inc. Recent Development
- 10.4 Novo Nordisk A/S
- 10.4.1 Novo Nordisk A/S Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.4.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.4.5 Novo Nordisk A/S Recent Development
- 10.5 Pfizer Inc.
- 10.5.1 Pfizer Inc. Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.5.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.5.5 Pfizer Inc. Recent Development
- 10.6 Teva Pharmaceuticals Ltd.
- 10.6.1 Teva Pharmaceuticals Ltd. Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.6.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.6.5 Teva Pharmaceuticals Ltd. Recent Development
- 10.7 Therapeutics MD, Inc.
- 10.7.1 Therapeutics MD, Inc. Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.7.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.7.5 Therapeutics MD, Inc. Recent Development
- 10.8 Shionogi & Company
- 10.8.1 Shionogi & Company Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.8.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.8.5 Shionogi & Company Recent Development
- 10.9 Allergan plc
- 10.9.1 Allergan plc Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.9.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.9.5 Allergan plc Recent Development
- 10.10 Shionogi & Co. Ltd.
- 10.10.1 Shionogi & Co. Ltd. Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
- 10.10.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 10.10.5 Shionogi & Co. Ltd. Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Postmenopausal Vaginal Atrophy Drugs Sales Channels
- 11.2.2 Postmenopausal Vaginal Atrophy Drugs Distributors
- 11.3 Postmenopausal Vaginal Atrophy Drugs Customers
12 Market Forecast
- 12.1 Global Postmenopausal Vaginal Atrophy Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type
- 12.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application
- 12.4 Postmenopausal Vaginal Atrophy Drugs Forecast by Regions
- 12.4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Postmenopausal Vaginal Atrophy Drugs. Industry analysis & Market Report on Postmenopausal Vaginal Atrophy Drugs is a syndicated market report, published as Global (United States, European Union and China) Postmenopausal Vaginal Atrophy Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Postmenopausal Vaginal Atrophy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
